Completed PHASE3 INTERVENTIONAL NCT00191321

Teriparatide Use in Hip Replaced Subjects

TUHRS Study - Teriparatide Use in Hip Replaced Subjects A Pilot Study on the Use of Teriparatide in Severe Osteoporotic Women With Hip Fracture and Submitted to Hip Replacement

Sponsor: Eli Lilly and Company

Conditions Osteoporosis

Interventions Teriparatide

Updated 6 times since 2017 Last updated: Jan 24, 2007 Started: Jul 31, 2004 Completion: Dec 31, 2005

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT00191321, this PHASE3 trial focuses on Osteoporosis and remains completed. Sponsored by Eli Lilly and Company, it has been updated 6 times since 2004, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

Change History

6 versions recorded

Sep 2025 — Present [monthly]

Completed PHASE3
Sep 2024 — Sep 2025 [monthly]

Completed PHASE3
Jul 2024 — Sep 2024 [monthly]

Completed PHASE3
Jan 2021 — Jul 2024 [monthly]

Completed PHASE3
Jun 2018 — Jan 2021 [monthly]

Completed PHASE3

▶ Show 1 earlier version

Jan 2017 — Jun 2018 [monthly]

Completed PHASE3

First recorded

Jul 2004

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Eli Lilly and Company

Data source: Eli Lilly and Company

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Alghero, Italy , Bergamo, Italy , Florence, Italy , Genova, Italy , Milan, Italy , Monza, Italy , Palermo, Italy , Pietra Ligure, Italy , Siena, Italy , Treviglio, Italy and 1 more location